{"links":{"feed":"https://www.erudio.com/reports/izabright-bladder01-nct07106762/feed.json","html":"https://www.erudio.com/reports/izabright-bladder01-nct07106762","json":"https://www.erudio.com/reports/izabright-bladder01-nct07106762.json","markdown":"https://www.erudio.com/reports/izabright-bladder01-nct07106762.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"izabright-bladder01-nct07106762"}},"request":"https://www.erudio.com/contact?report=izabright-bladder01-nct07106762"},"offer":{"cited_clinicians":4,"cited_commentary_sources":8,"verified_hcp_statements":16,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":5},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"izabright-bladder01-nct07106762"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=izabright-bladder01-nct07106762","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/izabright-bladder01-nct07106762","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 16 verified statements · 9 from 4 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-19T18:03:20.788364Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":7,"no_commentary_found":5},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Phase 3: Progression-Free Survival (PFS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":0,"title":"Primary endpoint: Phase 3: Overall Survival (OS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":5,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T7","registry_field":"armsInterventionsModule.interventions","source_count":0,"title":"Safety and tolerability"},{"claim_count":1,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":1,"title":"Design and conduct"},{"claim_count":4,"coverage":"discussed","id":"A1","source_count":2,"title":"External post-EV/P platinum estimates and fitness-dependent trial preference"},{"claim_count":2,"coverage":"discussed","id":"A2","source_count":2,"title":"Biomarker-directed alternatives and upfront testing"},{"claim_count":4,"coverage":"discussed","id":"A3","source_count":1,"title":"ADC switching, resistance biology and NECTIN4 uncertainty"},{"claim_count":3,"coverage":"discussed","id":"A4","source_count":3,"title":"Post-EV/P research priorities and referral access"}],"counts":{"beyond_population_findings":3,"beyond_population_statements":9,"cited_clinicians":4,"cited_clinicians_by_role":{"physician":3,"physician, Medical oncology":1},"cited_physicians":4,"cited_sources":8,"claims_by_expression_type":{"experience":1,"interpretation":3,"opinion":6,"question":2,"restatement":4},"claims_by_kind":{"source_observation":16},"clinician_statements":9,"evidence_units":10,"findings":5,"organisational_accounts":3,"people_cited":5,"people_identity_verified":5,"people_total":5,"screened_sources":12,"verified_claims":16},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":2},"limitations":3,"links":{"context":0,"support":3},"ma_question":true,"named_voices":2,"passages":2,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Iza-bren versus platinum: why a clinician supports the comparison","title_holders":{"cited_claim_ids":["claim-b2f07bdede0603e2f408"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"3 statements from 2 speakers in 1 source","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician"},{"cited_clinicians":0,"id":"F2","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":1},"limitations":4,"links":{"context":1,"support":4},"ma_question":true,"named_voices":0,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Platinum after EV plus pembrolizumab: what speakers say","evidence_line":"4 statements in 2 sources"},{"cited_clinicians":1,"id":"F3","population":"beyond","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":1},"limitations":2,"links":{"context":1,"support":2},"ma_question":true,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"FGFR3/HER2: what speakers say","evidence_line":"2 statements from 1 speaker in 2 sources"},{"cited_clinicians":1,"id":"F4","population":"beyond","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":3},"limitations":2,"links":{"context":0,"support":4},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"NECTIN4 after EV resistance: what a clinician asks about its validity","title_holders":{"cited_claim_ids":["claim-56d55e18fec11a37565d"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"4 statements from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F5","population":"beyond","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":0,"views":2},"limitations":3,"links":{"context":0,"support":3},"ma_question":true,"named_voices":1,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"EV plus pembrolizumab resistance: why a clinician stresses trials and research access","title_holders":{"cited_claim_ids":["claim-825c3997648d43ab73c5"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"3 statements from 1 speaker in 3 sources","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"}],"open_question":{"basis":"From findings F1 (3 statements from 2 speakers in 1 source) and F2 (4 statements in 2 sources)","cited_claim_ids":["claim-49e72a8fcd7e68360ef0","claim-db1c5ef4d6a5b4f80e9d","claim-b2f07bdede0603e2f408","claim-a7243d7f8c22818a7eaf","claim-2fa534e59c32224543d2","claim-1ca399264b83e4ced975","claim-36607ab41ef75e61fb15"],"finding_ids":["F1","F2"],"question":"What do clinicians need IZABRIGHT-Bladder01’s randomized comparison to establish about the activity of izalontamab brengitecan versus platinum before choosing second-line treatment after enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One X account welcomes the platinum comparison for an unresolved post-EV/P decision"},{"id":"section-2","level":2,"title":"Two organizational X accounts relay different platinum estimates and a fitness-dependent trial preference"},{"id":"section-3","level":2,"title":"Beyond the trial population"},{"id":"section-4","level":3,"title":"One relayed review prioritizes testing before attrition removes options"},{"id":"section-5","level":3,"title":"One X account questions NECTIN4 validity while favoring biologically informed ADC switching"},{"id":"section-6","level":3,"title":"One source-described trial participant links research priority with referral access"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507"},{"findings":[],"id":"T2","label":"Primary endpoint: Phase 3: Progression-Free Survival (PFS)"},{"findings":[],"id":"T3","label":"Primary endpoint: Phase 3: Overall Survival (OS)"},{"findings":[],"id":"T4","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1}],"id":"T5","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":2}],"id":"T6","label":"The comparison"},{"findings":[],"id":"T7","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-19T18:03:20.788364Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-19T18:52:55Z","record_hash":"23573a4b57b4cd9ba755bf655d71da5c043931865c5679b5259fcf89a22de778","release_hash":"ef7f618cb97b794dcc2d7b323df6224f1972f9d6e0cc15c8ab9ba44be7421747","report_id":"erudio-nct07106762","run_id":"b1be9660-bf35-45af-8e1a-58cf3a061c02","schema_version":"5.0","slug":"izabright-bladder01-nct07106762","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A physician supports the rationale for IZABRIGHT-Bladder01 amid another speaker’s description of unresolved treatment choices after EV/P. Direct trial commentary is limited; the broader sequencing context includes differing estimates of platinum activity, without enough study detail to reconcile them. These comments cannot establish the trial’s comparative benefit or safety.","examples":[],"meta_description":"12 sources screened · 16 verified statements (9 from clinicians verified by NPI or staff page) from 8 sources · 5 findings. Updated Nov 19, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-19T18:52:55Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":12},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on emerging treatment alternatives and targets for metastatic urothelial cancer after EVP; a question about additional treatment options after immunotherapy-based treatment in metastatic urothelial cancer.","26 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 39 sources about other trials or topics are not included.","The sources reviewed for this edition span October 2025–November 2026 and are limited to selected X discussions and summaries; their frequency does not measure how widely clinicians hold a view.","Discussion using neither the trial identifier nor recognizable study or drug names, or using different acronyms, may be missing.","No protocol or publication specific to NCT07106762 was identified in the reviewed material. Drug-label coverage was incomplete, and no exact Iza-bren label was identified; these discussions cannot establish a complete benefit–risk profile.","The platinum estimates lack sufficient study and patient detail for direct comparison. Neither describes IZABRIGHT-Bladder01 arm outcomes.","Two speakers relay attributed views; they are not additional clinician speakers. Reposts and quotations alone do not establish endorsement.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","No reviewed statement appraises the trial’s dose selection, its PFS or OS endpoint performance, or comparative safety. Silence on these subjects is not reassurance."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":8,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":8},"count":8,"evidence_window":{"end":"2026-11-17","start":"2025-10-26"},"retrieval_snapshot":"2026-11-19T17:11:35.455141Z","timeline":[{"count":1,"week":"2025-W43"},{"count":1,"week":"2026-W12"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W45"},{"count":2,"week":"2026-W46"},{"count":2,"week":"2026-W47"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07106762:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07106762:context","quote_policy":"short_quote_link_out"},{"id":"openfda:93edf309-993c-48ec-be90-27d89c86b62b:20261112","quote_policy":"short_quote_link_out"},{"id":"openfda:3aef8dbc-34d0-4150-89f0-3b16cf0fbfdb:20261026","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1982483153886568501:c70dd3af-a50b-4228-82a9-b5297b8b2602","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2028179789698195642:97278fc2-83e6-42f8-8a85-d49c47946c7c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2035398149905199243:19dd22a8-e111-4aa3-b96f-e1697683d47a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2043781323706241142:655acda3-6e23-4c93-bfaa-7d9a251fdc9d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089770939512697233:93c978f9-ce47-4d1e-8dbc-82b043bb951a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100911474352767471:7e17a0cd-1467-4b7f-939b-51bfc27999d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2118660973615845859:0ecbb745-95a8-4c9c-80f1-3b605e00b9f7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2120635047023886588:85509a16-224a-4f0d-b82c-c34b0edfaf17","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2120879662511403378:0a9762f1-f8ba-435c-9437-abc39c97c67c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2120896801343455565:3eec0482-5a22-471d-9ec3-d36525b51bda","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2122374387542471009:7e62f6c6-8fd3-4247-9de0-76d3a75e16ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2122770496911458357:34c0d688-cdaa-480d-9dac-0343f1b9623e","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":12,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":12},"count":12,"evidence_window":{"end":"2026-11-17","start":"2025-10-26"},"retrieval_snapshot":"2026-11-19T17:11:35.489822Z","timeline":[{"count":1,"week":"2025-W43"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W12"},{"count":1,"week":"2026-W16"},{"count":1,"week":"2026-W34"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W45"},{"count":3,"week":"2026-W46"},{"count":2,"week":"2026-W47"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":16,"x_video":0,"youtube":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"izalontamab brengitecan","slug":"izalontamab-brengitecan"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":["Gemzar"],"label":"gemcitabine","slug":"gemcitabine"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Urothelial carcinoma","slug":"urothelial-carcinoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"IZABRIGHT-Bladder01","aliases":["IZABRIGHT-Bladder01","CA244-0012","Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy","IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment"],"brief_title":"Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Urothelial Cancer"],"display_condition":"metastatic urothelial cancer with progression after immunotherapy","display_interventions":[["izalontamab brengitecan"]],"enrollment":{"count":470,"type":"ESTIMATED"},"interventions":[{"name":"Iza-bren","synonyms":["BMS-986507","BL-B01D1","Izalontamab brengitecan"],"type":"DRUG"},{"name":"Cisplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Gemcitabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT07106762","official_title":"IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment","overall_status":"RECRUITING","phase":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2029-01-26","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507","timeFrame":"Approximately 3 months"},{"description":"Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)","measure":"Phase 3: Progression-Free Survival (PFS)","timeFrame":"Up to 5 years"},{"measure":"Phase 3: Overall Survival (OS)","timeFrame":"Up to 5 years"}],"registered_date":{"date":"2025-08-06","type":"ACTUAL"},"registry_last_updated":"2026-07-29","registry_url":"https://clinicaltrials.gov/study/NCT07106762","short_name":"IZABRIGHT-Bladder01","short_name_basis":"canonical_name","sponsor":"Bristol-Myers Squibb","start_date":{"date":"2025-09-30","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2, phase3","study_ids":[{"id":"CA244-0012","type":"sponsor_study_id"},{"domain":"2025-522400-24","id":"EU CTR","type":"other"},{"domain":"U1111-1322-9071","id":"WHO","type":"other"}],"study_type":"INTERVENTIONAL"}}}